National Institute on Drug Abuse; Notice of Closed Meetings, 12194-12195 [2021-04299]
Download as PDF
<![CDATA[
12194
Federal Register / Vol. 86, No. 39 / Tuesday, March 2, 2021 / Notices
and Supporting Regulations; Form
Number: CMS–372(S); and OMB Control
Number: 0938–0272. Through the
publication of this document we are
withdrawing that notice (FR document:
2021–03916) in its entirety. While the
notice published in error, it will be
resubmitted for publication and public
comment when ready.
Dated: February 25, 2021.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2021–04296 Filed 3–1–21; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Secretary’s Advisory
Committee on Human Research
Protections
Department of Health and
Human Services, Office of the Secretary,
Office of the Assistant Secretary for
Health.
ACTION: Notice.
AGENCY:
Pursuant to Section 10(a) of
the Federal Advisory Committee Act,
U.S.C. Appendix 2, notice is hereby
given that the Secretary’s Advisory
Committee on Human Research
Protections (SACHRP) will hold a
meeting that will be open to the public.
Information about SACHRP, the full
meeting agenda, and instructions for
linking to public access will be posted
on the SACHRP website at https://
www.dhhs.gov/ohrp/sachrp-committee/
meetings/.
DATES: The meeting will be held on
Tuesday, March 23rd, 2021, from 11:00
a.m. until 4:30 p.m., and Wednesday,
March 24, 2021, from 11:00 a.m. until
4:30 p.m. (times are tentative and
subject to change). The confirmed times
and agenda will be posted on the
SACHRP website when this information
becomes available.
ADDRESSES: This meeting will be held
via webcast. Members of the public may
also attend the meeting via webcast.
Instructions for attending via webcast
will be posted one week prior to the
meeting at https://www.hhs.gov/ohrp/
sachrp-committee/meetings/.
FOR FURTHER INFORMATION CONTACT: Julia
Gorey, J.D., Executive Director,
SACHRP; U.S. Department of Health
and Human Services, 1101 Wootton
Parkway, Suite 200, Rockville,
Maryland 20852; telephone: 240–453–
8141; fax: 240–453–6909; email address:
SACHRP@hhs.gov.
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:11 Mar 01, 2021
Jkt 253001
Under the
authority of 42 U.S.C. 217a, Section 222
of the Public Health Service Act, as
amended, SACHRP was established to
provide expert advice and
recommendations to the Secretary of
Health and Human Services, through
the Assistant Secretary for Health, on
issues and topics pertaining to or
associated with the protection of human
research subjects.
The Subpart A Subcommittee (SAS)
was established by SACHRP in October
2006 and is charged with developing
recommendations for consideration by
SACHRP regarding the application of
subpart A of 45 CFR part 46 in the
current research environment.
The Subcommittee on Harmonization
(SOH) was established by SACHRP at its
July 2009 meeting and charged with
identifying and prioritizing areas in
which regulations or guidelines for
human subjects research adopted by
various agencies or offices within HHS
would benefit from harmonization,
consistency, clarity, simplification or
coordination.
The SACHRP meeting will open to the
public at 11:00 a.m., on Tuesday, March
23, 2021, followed by opening remarks
from Dr. Jerry Menikoff, Director of
OHRP and Dr. Douglas Diekema,
SACHRP Chair. The meeting will begin
with presentation of recommendations
on Justice as an Ethical Concept in 45
CFR 46, followed by an expert panel
discussion of draft recommendations on
Mandatory Exploratory Biopsies in
Research. The day will conclude with
discussion of a new SACHRP topic, IRB
Authority to Restrict Use of Data in
Research. March 24th will include
presentation of Interactions between
Sponsors, Clinical Trial Sites, and
Research Subjects, and lastly,
Consideration of Risks to Bystanders in
Research. Other topics may be added;
for the full and updated meeting agenda,
see https://www.dhhs.gov/ohrp/sachrpcommittee/meetings/.
The public will have an opportunity
to send comments to SACHRP during
the meeting’s public comment session
or to submit written public comments in
advance. Persons who wish to provide
public comments should review
instructions at https://www.hhs.gov/
ohrp/sachrp-committee/meetings/
index.html and respond by midnight
Wednesday, March 18th, 2021, ET.
Individuals submitting written
statements as public comment should
submit their comments to SACHRP at
SACHRP@hhs.gov. Comments are
limited to three minutes each.
Time will be allotted for public
comment on both days. Note that public
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
comment must be relevant to topics
currently being addressed by SACHRP.
Dated: February 22, 2021.
Julia G. Gorey,
Executive Director, SACHRP, Office for
Human Research Protections.
[FR Doc. 2021–04244 Filed 3–1–21; 8:45 am]
BILLING CODE 4150–36–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA–
L Conflict SEP.
Date: March 25, 2021
Time: 11:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Preethy Nayar, Ph.D.
Scientific Review Officer Scientific Review
Branch National Institute on Drug Abuse,
NIH 301 North Stonestreet Avenue Bethesda,
MD 20892, 301–443–4577, nayarp2@
csr.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Implementing the HIV Service Cascade for
Justice-Involved Populations (U01—Clinical
Trial Optional).
Date: March 30, 2021.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Sheila Pirooznia, Ph.D.;
Scientific Review Officer, Division of
Extramural Review, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue Bethesda,
MD 20892, (301) 496–9350 sheila.pirooznia@
nih.gov.
E:\FR\FM\02MRN1.SGM
02MRN1
Federal Register / Vol. 86, No. 39 / Tuesday, March 2, 2021 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: February 24, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–04299 Filed 3–1–21; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Martin Delaney
Collaboratories for HIV Cure Research (UM1
Clinical Trial Not Allowed); Martin Delaney
Collaboratory for Pediatric HIV Cure
Research (UM1 Clinical Trial Not Allowed)
Date: March 30–31, 2021.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G11A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: J. Bruce Sundstrom, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G11A Rockville, MD
20852, 240–669–5045, sundstromj@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
VerDate Sep<11>2014
17:11 Mar 01, 2021
Jkt 253001
Dated: February 24, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–04297 Filed 3–1–21; 8:45 am]
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
BILLING CODE 4140–01–P
12195
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement (U01
Clinical Trial Required)
Date: April 22–23, 2021.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G13B,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Yong Gao, Ph.D., Scientific
Review Officer, Scientific Review Program,
Division of Extramural Activities, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health 5601 Fishers
Lane, Room 3G13B Rockville, MD 20852
(240) 669–5048 yong.gao@nih.gov
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 24, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–04300 Filed 3–1–21; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; BRAIN Biology and
Biophysics of Neural Stimulations and
Recording Technologies.
Date: March 23, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Mirela Milescu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20852,
mirela.milescu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: February 24, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–04298 Filed 3–1–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Library of
E:\FR\FM\02MRN1.SGM
02MRN1
]]>Agencies
[Federal Register Volume 86, Number 39 (Tuesday, March 2, 2021)]
[Notices]
[Pages 12194-12195]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04299]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA-L Conflict SEP.
Date: March 25, 2021
Time: 11:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D. Scientific Review Officer
Scientific Review Branch National Institute on Drug Abuse, NIH 301
North Stonestreet Avenue Bethesda, MD 20892, 301-443-4577,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Implementing the HIV Service Cascade for Justice-
Involved Populations (U01--Clinical Trial Optional).
Date: March 30, 2021.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Sheila Pirooznia, Ph.D.; Scientific Review
Officer, Division of Extramural Review, Scientific Review Branch,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue
Bethesda, MD 20892, (301) 496-9350 [email protected].
[[Page 12195]]
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 24, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-04299 Filed 3-1-21; 8:45 am]
BILLING CODE 4140-01-P
